Onyx Pharmaceuticals (ONXX) +38.2% premarket after yesterday's FDA panel vote in favor of the...


Onyx Pharmaceuticals (ONXX) +38.2% premarket after yesterday's FDA panel vote in favor of the company's Kyprolis drug for multiple myeloma. The final FDA approval decision is expected July 27. Shares are upgraded to Outperform from Neutral at Baird, initiated with a Buy at Deutsche Bank, and upgraded to Buy at Brean Murray.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs